Home » Stocks » IMNM

Immunome, Inc. (IMNM)

Stock Price: $21.98 USD -0.52 (-2.31%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 236.72M
Revenue (ttm) n/a
Net Income (ttm) -17.84M
Shares Out 10.66M
EPS (ttm) -5.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $21.98
Previous Close $22.50
Change ($) -0.52
Change (%) -2.31%
Day's Open 22.67
Day's Range 21.50 - 23.00
Day's Volume 45,818
52-Week Range 9.28 - 63.78

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

In addition to encouraging preclinical data from the COVID-19 antibody cocktail announced today, Immunome Inc (NASDAQ: IMNM) has entered into a private placement agreement of approximately $27 million w...

1 week ago - Benzinga

Immunome Inc (NASDAQ: IMNM) has announced antibody selection for its IMM-BCP-01 antibody cocktail and shared preclinical data showing that IMM-BCP-01 is effective against the current SARS-CoV-2 and its ...

1 week ago - Benzinga

EXTON, Pa.--(BUSINESS WIRE)--Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Heads Toward IND Filing

1 week ago - Business Wire

EXTON, Pa.--(BUSINESS WIRE)--Immunome Announces $27 Million Private Placement

1 week ago - Business Wire

EXTON, Pa.--(BUSINESS WIRE)--Immunome announces the appointment of Corleen Roche as Chief Financial Officer

2 weeks ago - Business Wire

EXTON, Pa.--(BUSINESS WIRE)--Immunome appoints Dennis Giesing, Ph.D. to the role of Chief Development Officer

1 month ago - Business Wire

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody th...

1 month ago - Business Wire

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics,...

1 month ago - Business Wire

The recent IPO's coronavirus antibody breakthrough could be a game changer in the fight against COVID-19.

2 months ago - The Motley Fool

Immunome (IMNM) stock is rocketing higher on Thursday after announcing an update concerning its vaccine research for the novel coronavirus. The post IMNM Stock: The Big News That Has Biotech Play Immuno...

2 months ago - InvestorPlace

Shares of micro-cap biopharma Immunome Inc (NASDAQ: IMNM) are indicated to open Thursday's session sharply higher. What Happened: Immunome, which focuses on developing antibody therapies, said its disco...

2 months ago - Benzinga

EXTON, Pa.--(BUSINESS WIRE)--Immunome announces that its discovery engine has isolated potent antibodies capable of neutralizing several SARS-CoV-2 variants

2 months ago - Business Wire

EXTON, Pa. & SAN DIEGO--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody t...

3 months ago - Business Wire

EXTON, Pa.--(BUSINESS WIRE)--Immunome announces the release of findings from its ongoing preclinical COVID-19 research program

3 months ago - Business Wire

EXTON, Pa.--(BUSINESS WIRE)--Immunome appoints Richard Baron to BOD and Sandra Stoneman as Chief Legal Officer and Corporate Secretary

4 months ago - Business Wire

EXTON, Pa.--(BUSINESS WIRE)--Immunome Reports Third Quarter 2020 Financial Results and Significant Progress

5 months ago - Business Wire

EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics,...

6 months ago - Business Wire

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...

Other stocks mentioned: ESI, SELB, AVO, CCXX, LUNG
6 months ago - Benzinga

EXTON, Pa.--(BUSINESS WIRE)--Immunome Announces Pricing of Upsized Initial Public Offering

7 months ago - Business Wire

Immunome Aims For $30 Million U.S. IPO

7 months ago - Seeking Alpha

Immunome Inc. set terms for its initial public offering, in which the Pennsylvania-based biopharmaceutical company focused on oncology looks to raise up to $32.5 million. The company is offering 2.5 mil...

7 months ago - Market Watch

About IMNM

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Industry
Biotechnology
IPO Date
Oct 2, 2020
Stock Exchange
NASDAQ
Ticker Symbol
IMNM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Immunome stock is "Strong Buy." The 12-month stock price forecast is 36.00, which is an increase of 63.79% from the latest price.

Price Target
$36.00
(63.79% upside)
Analyst Consensus: Strong Buy